Clinical Trial

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

Completed Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (RO7247669) in combination with platinum-based chemotherapy compared with pembrolizumab plus platinum-based chemotherapy in participants with previously untreated, locally advanced, unresectable (Stage IIIB/IIIC) or metastatic (Stage IV) non-small-cell lung cancer (NSCLC) who are not eligible to receive curative surgery and/or definitive chemoradiotherapy.
Protocol Amendment History 2 changes
critical Trial completed 2026-07-21
minor Completion moved earlier: 2026-06-01 -> 2026-04-30 2026-07-21
Trial Details
NCT Number NCT05775289
Lead Sponsor Hoffmann-La Roche
Conditions Non-small Cell Lung Cancer
Enrollment 182 participants
Start Date 2023-03-15
Primary Completion 2024-06-20 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-20